The role of anthracyclines in second-line therapy of ovarian cancer-Reference-Cited by-同舟云学术

The role of anthracyclines in second-line therapy of ovarian cancer

Published:2003-11 Issue:s2 Volume:13 Page:178-184
ISSN:1048-891X
Container-title:International Journal of Gynecological Cancer
language:en
Short-container-title:Int J Gynecol Cancer

Author:

Vermorken J. B.

Publisher

BMJ

Subject

Obstetrics and Gynecology,Oncology

Reference41 articles.

1. 1 J Ferlay, F Bray, P Pisani, and DM. Parkin GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancerbase No. 5, Lyon: Iarcpress; 2001 .

2. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer

3. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering a hyaluronic acid-encapsulated tumor-targeted nanoplatform with sensitized chemotherapy and a photothermal effect for enhancing tumor therapy;International Journal of Biological Macromolecules;2024-04

2. A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins;Scientific Reports;2024-03-01

3. The isolation, structural characterization and anti-osteosarcoma activity of a water soluble polysaccharide from Agrimonia pilosa;Carbohydrate Polymers;2018-05

4. Hypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance;Nature Communications;2017-06-21

5. Preparation and drug controlled release of porous octyl-dextran microspheres;Journal of Biomaterials Science, Polymer Edition;2015-08-20